Shore Capital is pleased to have acted as Joint Bookrunner on a £9.9m conditional placing and retail offer for Oxford BioDynamics plc (AIM: OBD).

Oxford BioDynamics is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests.

The fundraising will provide working capital to support the ongoing commercial development of the EpiSwitch® product line, through continued investment in sales and marketing activities.

Shore Capital has acted as Nominated Advisor and Broker to the company since January 2018 and we look forward to continuing our work with the OBD team.

For further information please contact:  

Shore Capital +44 (0) 20 7408 4090

Corporate Advisory: Stephane Auton, Iain Sexton

Corporate Broking: Fiona Conroy

For Shore Capital media enquiries, please contact:  

[email protected]